Skip to content

Study · Measured the body's own peptide · 1984

6 results

Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease.

O'Morain C, Bishop AE, McGregor GP, Levi AJ, Bloom SR, Polak JM, Peters TJ

Gut1 Jan 1984Cited by 69 (Europe PMC)

PMID6360814 (opens in a new tab)PMCIDPMC1432236 (opens in a new tab)DOI10.1136/gut.25.1.57 (opens in a new tab)PepBankPUB-06360814
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    Ten of 17 rectal biopsies from patients with ulcerative colitis showed a normal pattern of VIP innervation.

    In plain wordsIn people with ulcerative colitis, ten of 17 biopsies showed a normal pattern of the body's own VIP nerves.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    MixedVIP innervation pattern in ulcerative colitis
    Study

    n = 17

    Comparator
    Normal controls
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    Ten of the 17 biopsies examined from ulcerative colitics showed a normal pattern of VIP innervation.
    1 context sentence
    Summary · context
    Vasoactive intestinal polypeptide (VIP)-containing nerves and VIP content of endoscopic rectal biopsies from 47 patients with inflammatory bowel disease and 17 normal controls were examined by immunocytochemistry and radioimmunoassay.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In rectal biopsies from patients with Crohn's disease, immunocytochemistry showed more VIP nerves, with abnormal appearance, including patients without rectal disease.

    In plain wordsIn people with Crohn's disease, the body's own VIP nerves were increased in rectal biopsies compared with controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP-containing nerves in Crohn's disease
    Study

    n: not reported in source

    Comparator
    Normal controls
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    Immunocytochemistry revealed a consistent increase in, and abnormal appearance of, VIP nerves in patients with Crohn's disease not only those with rectal involvement but also patients with no histological evidence of rectal disease.
    1 context sentence
    Summary · context
    Vasoactive intestinal polypeptide (VIP)-containing nerves and VIP content of endoscopic rectal biopsies from 47 patients with inflammatory bowel disease and 17 normal controls were examined by immunocytochemistry and radioimmunoassay.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Rectal biopsies from patients with rectal Crohn's disease contained 3.43 +/- 1.24 pmol VIP/mg protein versus 1.64 +/- 0.39 in normal controls.

    In plain wordsIn people with rectal Crohn's disease, the body's own VIP content in biopsies was higher than in controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP content in rectal Crohn's disease
    Study

    n: not reported in source

    Comparator
    Normal controls
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Measurements

    VIP content
    3.43 pmol/mg protein
    rectal Crohn's disease
    VIP content
    1.64 pmol/mg protein
    normal controls

    Source sentences

    Summary
    Normal control biopsies contained 1.64 +/- 0.39 pmol VIP/mg protein as compared with 3.43 +/- 1.24 pmol VIP/mg protein in tissue from patients with rectal Crohn's disease and 5.37 +/- 1.23 pmol VIP/mg protein in those with Crohn's disease without rectal involvement.
    1 context sentence
    Summary · context
    Vasoactive intestinal polypeptide (VIP)-containing nerves and VIP content of endoscopic rectal biopsies from 47 patients with inflammatory bowel disease and 17 normal controls were examined by immunocytochemistry and radioimmunoassay.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    Biopsies from patients with Crohn's disease without rectal involvement contained 5.37 +/- 1.23 pmol VIP/mg protein versus 1.64 +/- 0.39 in normal controls.

    In plain wordsIn people with Crohn's disease without rectal disease, the body's own VIP content in biopsies was higher than in controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP content in Crohn's disease without rectal involvement
    Study

    n: not reported in source

    Comparator
    Normal controls
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Measurements

    VIP content
    5.37 pmol/mg protein
    Crohn's disease without rectal involvement
    VIP content
    1.64 pmol/mg protein
    normal controls

    Source sentences

    Summary
    Normal control biopsies contained 1.64 +/- 0.39 pmol VIP/mg protein as compared with 3.43 +/- 1.24 pmol VIP/mg protein in tissue from patients with rectal Crohn's disease and 5.37 +/- 1.23 pmol VIP/mg protein in those with Crohn's disease without rectal involvement.
    1 context sentence
    Summary · context
    Vasoactive intestinal polypeptide (VIP)-containing nerves and VIP content of endoscopic rectal biopsies from 47 patients with inflammatory bowel disease and 17 normal controls were examined by immunocytochemistry and radioimmunoassay.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelObservational studyOther

    In ulcerative colitis biopsies, only areas with obvious active proctitis had increased VIP nerves, and these nerves had a normal morphology, unlike in Crohn's disease.

    In plain wordsIn ulcerative colitis, only inflamed areas had more of the body's own VIP nerves, and the nerves looked normal.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    MixedVIP nerves in areas of active proctitis in ulcerative colitis
    Study

    n: not reported in source

    Comparator
    Normal controls
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    Examination of the conventional histology of these biopsies showed that only areas with obvious active proctitis had increased VIP nerves and, unlike the appearance in Crohn's disease, these nerves had a normal morphology.
    1 context sentence
    Summary · context
    Vasoactive intestinal polypeptide (VIP)-containing nerves and VIP content of endoscopic rectal biopsies from 47 patients with inflammatory bowel disease and 17 normal controls were examined by immunocytochemistry and radioimmunoassay.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  6. 06HumanEndogenous levelObservational studyOther

    The VIP content of ulcerative colitis biopsies, 1.34 +/- 0.37 pmol/mg protein, was similar to that of controls.

    In plain wordsIn people with ulcerative colitis, the body's own VIP content in biopsies was similar to that of controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP content in ulcerative colitis biopsies
    Study

    n: not reported in source

    Comparator
    Normal controls
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Measurements

    VIP content
    1.34 pmol/mg protein
    ulcerative colitis

    Source sentences

    Summary
    The VIP content of these biopsies was similar to that of the controls; 1.34 +/- 0.37 pmol/mg protein.
    1 context sentence
    Summary · context
    Vasoactive intestinal polypeptide (VIP)-containing nerves and VIP content of endoscopic rectal biopsies from 47 patients with inflammatory bowel disease and 17 normal controls were examined by immunocytochemistry and radioimmunoassay.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.